Di Sandro Stefano, Danieli Maria, Ferla Fabio, Lauterio Andrea, De Carlis Riccardo, Benuzzi Laura, Buscemi Vincenzo, Pezzoli Isabella, De Carlis Luciano
Department of General Surgery and Transplantation, Niguarda Ca' Granda Hospital, Milan, Italy.
Niguarda Transplant Foundation, Niguarda Ca' Granda Hospital, Milan, Italy.
Transl Gastroenterol Hepatol. 2018 Sep 18;3:68. doi: 10.21037/tgh.2018.08.05. eCollection 2018.
The use of laparoscopic liver resection (LLR) has progressively spread in the last 10 years. Several studies have shown the superiority of LLR to open liver resection (OLR) in term of perioperative outcomes. With this review, we aim to systematically assess short-term and long-term major outcomes in patients who underwent LLR for hepatocellular carcinoma (HCC) in order to illustrate the advantages of minimally invasive liver surgery. Through an advanced PubMed research, we selected all retrospective, prospective, and comparative clinical trials reporting short-term and long-term outcomes of any series of patients with diagnosis of HCC who underwent laparoscopic or robotic resection. Reviews, meta-analyses, or case reports were excluded. None of the patients included in this review has received a previous locoregional treatment for the same tumor nor has undergone a laparoscopic-assisted procedure. We considered morbidity and mortality for evaluation of major short-term outcomes, and overall survival (OS) and disease-free survival (DFS) for evaluation of long-term outcomes. A total of 1,501 patients from 17 retrospective studies were included, 15 studies compare LLR with OLR. Propensity-score matching (PSM) analysis was used in 11 studies (975 patients). The majority of the studies included patients with good liver function and a single HCC. Cirrhosis at pathology ranged from 33% to 100%. Overall mortality and morbidity ranges were 0-2.4% and 4.9-44% respectively, with most of the complications being Clavien-Dindo grade I or II (range: 3.9-23.3% . 0-9.52% for Clavien I-II and ≥ III respectively). The median blood loss ranged from 150 to 389 mL; the range of the median duration of surgery was 134-343 minutes. The maximum rate of conversion was 18.2%. The median duration of hospitalization ranged from 4 to 13 days. The ranges of overall survival rates at 1-, 3- and 5-year were 72.8-100%, 60.7-93.5% and 38-89.7% respectively. The ranges of disease free survival rates at 1-, 3- and 5-year were 45.5-91.5%, 20-72.2% and 19-67.8% respectively. The benefits of LLR in term of complication rate, blood loss, and duration of hospital stay make this procedure an advantageous alternative to OLR, especially for cirrhotic patients in whom the use of LLR reduces the risk of post-hepatectomy liver failure. The limits of LLR can be overcome by robotic surgery, which could therefore be preferred. Further benefits of minimally invasive surgery derive from its ability to reduce the formation of adhesions in view of a salvage liver transplant. In conclusion, the results of this review seem to confirm the safety and feasibility of LLR for HCC as well as its superiority to OLR according to perioperative outcomes.
在过去十年中,腹腔镜肝切除术(LLR)的应用逐渐普及。多项研究表明,在围手术期结局方面,LLR优于开放性肝切除术(OLR)。通过本综述,我们旨在系统评估接受LLR治疗肝细胞癌(HCC)患者的短期和长期主要结局,以阐明微创肝脏手术的优势。通过先进的PubMed检索,我们选择了所有报告任何系列诊断为HCC且接受腹腔镜或机器人切除术患者短期和长期结局的回顾性、前瞻性和比较性临床试验。排除综述、荟萃分析或病例报告。本综述纳入的患者均未接受过针对同一肿瘤的先前局部区域治疗,也未接受过腹腔镜辅助手术。我们将发病率和死亡率用于评估主要短期结局,将总生存期(OS)和无病生存期(DFS)用于评估长期结局。共纳入来自17项回顾性研究的1501例患者,15项研究比较了LLR与OLR。11项研究(975例患者)采用了倾向评分匹配(PSM)分析。大多数研究纳入了肝功能良好且为单个HCC的患者。病理检查显示肝硬化的比例在33%至100%之间。总体死亡率和发病率范围分别为0 - 2.4%和4.9 - 44%,大多数并发症为Clavien-Dindo I级或II级(范围:3.9 - 23.3%,Clavien I-II级为0 - 9.52%,≥ III级为0 - 9.52%)。术中中位失血量在150至389 mL之间;中位手术时长范围为134 - 343分钟。最大中转率为18.2%。中位住院时长在4至13天之间。1年、3年和5年的总生存率范围分别为72.8 - 100%、60.7 - 93.5%和38 - 89.7%。1年、3年和5年的无病生存率范围分别为45.5 - 91.5%、20 - 72.2%和19 - 67.8%。LLR在并发症发生率、失血量和住院时长方面的优势使其成为OLR的有利替代方案,尤其是对于肝硬化患者,LLR的应用降低了肝切除术后肝衰竭的风险。机器人手术可以克服LLR的局限性,因此可能更受青睐。鉴于挽救性肝移植,微创手术的进一步优势源于其减少粘连形成的能力。总之,本综述结果似乎证实了LLR治疗HCC的安全性和可行性以及根据围手术期结局其优于OLR。